Home › Funds › Duquesne Family Office LLC › RYTM
Duquesne Family Office LLC position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
Duquesne Family Office LLC reported holding 269,900 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.7M, representing 0.68% of its reported portfolio and ranking #32 among its reported holdings. Duquesne Family Office LLC has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Duquesne Family Office LLC's RYTM position evolved
Duquesne Family Office LLC first disclosed a stake in RYTM in Q2 2026 at 203,618 shares (US$22.6M). The position peaked in Q3 2026 at 269,900 shares, worth US$25.7M. Across 2 filings, Duquesne Family Office LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 269,900 shares valued at US$25.7M — an increase of 66,282 shares quarter over quarter.. Notable position changes include a 33% increase in Q3 2026 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 203.62K | $22.61M | New |
| Q3 2026 | 269.90K | $25.70M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$634.8M), BAKER BROS. ADVISORS LP (US$533.6M), PERCEPTIVE ADVISORS LLC (US$241.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $634.78M · Q3 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $533.63M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.53M sh · $241.14M · Q3 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.48M sh · $236.20M · Q3 2026
- Checkpoint Capital L.P. 1.22M sh · $115.84M · Q3 2026
- Siren, L.L.C. 1.09M sh · $103.43M · Q3 2026
- Rock Springs Capital Management LP 692.60K sh · $65.95M · Q3 2026
- Sofinnova Investments, Inc. 534.54K sh · $50.90M · Q3 2026
More on Duquesne Family Office LLC
FAQ
How long has Duquesne Family Office LLC held RYTM?
Duquesne Family Office LLC has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Duquesne Family Office LLC's current position in RYTM?
As of Q3 2026, Duquesne Family Office LLC holds 269.90K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $25.70M, representing 0.68% of its reported portfolio and ranking #32.
Has Duquesne Family Office LLC been buying or selling RYTM?
In the latest 13F filing (Q3 2026), Duquesne Family Office LLC increased its position in RYTM. The position peaked in Q3 2026 at 269.90K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.